Skip to main content

GSK's head of oncology jumps to Boston precision medicine startup

Under the new leadership, the startup is slated to begin clinical trials next year, make its drug pipeline public and — although the details haven't been ironed out yet — go public.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.